Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Change in Cash (2016 - 2025)

Historic Change in Cash for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $66.9 million.

  • Haemonetics' Change in Cash rose 21044.38% to $66.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $42.5 million, marking a year-over-year decrease of 6648.41%. This contributed to the annual value of $128.0 million for FY2025, which is 22110.14% up from last year.
  • Per Haemonetics' latest filing, its Change in Cash stood at $66.9 million for Q4 2025, which was up 21044.38% from $3.5 million recorded in Q3 2025.
  • Haemonetics' 5-year Change in Cash high stood at $165.6 million for Q2 2024, and its period low was -$157.0 million during Q4 2023.
  • Its 5-year average for Change in Cash is $8.7 million, with a median of $3.4 million in 2021.
  • In the last 5 years, Haemonetics' Change in Cash crashed by 81305.38% in 2023 and then surged by 1311859.54% in 2024.
  • Haemonetics' Change in Cash (Quarter) stood at $19.0 million in 2021, then crashed by 190.72% to -$17.2 million in 2022, then crashed by 813.05% to -$157.0 million in 2023, then soared by 113.73% to $21.6 million in 2024, then skyrocketed by 210.44% to $66.9 million in 2025.
  • Its Change in Cash was $66.9 million in Q4 2025, compared to $3.5 million in Q3 2025 and -$13.9 million in Q2 2025.